What do oncologists think of the AMPLIFY trial (CALQUENCE®)?
AMPLIFY — First-line (previously untreated) CLL/SLL — fixed-duration acalabrutinib + venetoclax
FDA APPROVED · Feb 2026FDA-approved February 19, 2026, as an all-oral, fixed-duration regimen: acalabrutinib in combination with venetoclax for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The AMPLIFY obinutuzumab-containing triplet arm is not FDA-approved in the US.
Physician voices — verbatim
Full physician voice list (8)
Full conference coverage and trial data: KOL Pulse trial profile coming soon.
What do oncologists think of the ECHO trial (CALQUENCE®)?
ECHO — First-line (previously untreated) mantle cell lymphoma in transplant-ineligible adults — acalabrutinib + bendamustine-rituximab
FDA APPROVED · Jan 2025FDA granted traditional (full) approval on January 16, 2025 to acalabrutinib with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem-cell transplantation. The 2017 accelerated approval in relapsed/refractory MCL was converted to traditional approval the same day.
Physician voices — verbatim
Full physician voice list (2)
| Physician | Comment (verbatim) | Sentiment | Impressions |
|---|---|---|---|
| Ajay Major, MD, MBA @majorajay |
ECHO Ph3 ABR in 1L MCL #18ICML - superior PFS with ABR in high-risk MCL - no diff OS - not enough TP53mut pts for dedicated analysis Thoughts from #lymsm on ABR vs sequential BR ▶️ acala? | Positive | 636 |
| Laura Korin @laura_korin |
#ASH24 abstracts relevant for LATAM -ECHO in pts with high risk mantle cell lymphoma. Are you adding a BTKi in induction in these subgroups? https://t.co/tZ3gw4syBE | Neutral | 466 |
Full conference coverage and trial data: KOL Pulse trial profile coming soon.
CALQUENCE® — FDA status
FDA APPROVEDCALQUENCE® (acalabrutinib) is an FDA-approved, second-generation Bruton tyrosine kinase (BTK) inhibitor from AstraZeneca for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). For the full, current list of FDA indications and prescribing information, see calquence.com or FDA label (DailyMed). KOL Pulse indexes the physician conversation; the label is owned and maintained by the manufacturer.
CALQUENCE® sentiment — FAQ
AMPLIFY
What do oncologists think of the AMPLIFY trial (CALQUENCE®)?
Across 8 verified physician voices in KOL Pulse's index for AMPLIFY, 25% expressed positive sentiment, 13% were nuanced (praising the result while flagging a caveat), 62% were neutral, and 0% were critical. Positive voices highlight an all-oral, fixed-duration, chemotherapy-free first-line option — the progression-free-survival benefit and deep MRD-negative responses of acalabrutinib plus venetoclax over chemoimmunotherapy; nuanced and critical voices flag immature overall survival and the need for longer follow-up, the added infection and toxicity (NRM) when obinutuzumab is added, and which patients truly need a triplet versus the all-oral doublet.
Where can I find the AMPLIFY trial data for CALQUENCE® (acalabrutinib)?
AMPLIFY is registered as NCT03836261 and studied CALQUENCE® (acalabrutinib) in First-line (previously untreated) CLL/SLL — fixed-duration acalabrutinib + venetoclax. KOL Pulse's AMPLIFY trial profile is coming soon.
ECHO
What do oncologists think of the ECHO trial (CALQUENCE®)?
Across 2 verified physician voices in KOL Pulse's index for ECHO, 50% expressed positive sentiment, 0% were nuanced (praising the result while flagging a caveat), 50% were neutral, and 0% were critical. Positive voices highlight the progression-free-survival benefit of adding acalabrutinib to bendamustine-rituximab as a first-line option for older, transplant-ineligible mantle cell lymphoma; nuanced and critical voices flag the lack of an overall-survival difference, tolerability in an older population, and how few TP53-mutated patients were enrolled for a dedicated analysis.
Where can I find the ECHO trial data for CALQUENCE® (acalabrutinib)?
ECHO is registered as NCT02972840 and studied CALQUENCE® (acalabrutinib) in First-line (previously untreated) mantle cell lymphoma in transplant-ineligible adults — acalabrutinib + bendamustine-rituximab. KOL Pulse's ECHO trial profile is coming soon.
Regulatory
Is CALQUENCE® (acalabrutinib) FDA approved?
CALQUENCE® is FDA-approved. KOL Pulse organizes this page by clinical trial and links out to the manufacturer's brand site and the FDA label for the full, current list of FDA indications and prescribing information — the label is owned and updated by the manufacturer, so we point to it rather than reproducing it.